Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome

Experimental Neurology

Volumn 239, Issue 1, 2013, Pages 229-234

  Hijazi, Maruan ^a   Fillat, Cristina ^b   Medina, José M ^a   Velasco, Ana ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Albumin; Differentiation; Down syndrome; DYRK1A; Oleic acid

Indexed keywords

CHOLINE ACETYLTRANSFERASE; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A; OLEIC ACID; PROLINE DIRECTED PROTEIN KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CONTROLLED STUDY; DOWN REGULATION; DOWN SYNDROME; DYRK1A GENE; ENZYME INDUCTION; EXPERIMENTAL MODEL; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; INHIBITION KINETICS; MENTAL DEFICIENCY; MOUSE; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TRISOMY 16;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE; CHOLINE O-ACETYLTRANSFERASE; DOWN SYNDROME; ENZYME INDUCTION; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; NERVE GROWTH FACTORS; OLEIC ACID; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; TRANSFECTION; TRISOMY;

EID: 84869866801     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.10.016     Document Type: Article

References (40)

1. Ahn K.J., Jeong H.K., Choi H.S., Ryoo S.R., Kim Y.J., Goo J.S., Choi S.Y., Han J.S., Ha I., Song W.J. DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects. Neurobiol. Dis. 2006, 22:463-472.
2. Allen D.D., Martin J., Arriagada C., Cardenas A.M., Rapoport S.I., Caviedes R., Caviedes P. Impaired cholinergic function in cell lines derived from the cerebral cortex of normal and trisomy 16 mice. Eur. J. Neurosci. 2000, 12:3259-3264.
3. Altafaj X., Dierssen M., Baamonde C., Marti E., Visa J., Guimera J., Oset M., Gonzalez J.R., Florez J., Fillat C., Estivill X. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Hum. Mol. Genet. 2001, 10:1915-1923.
4. Antonarakis S.E., Lyle R., Dermitzakis E.T., Reymond A., Deutsch S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat. Rev. Genet. 2004, 5:725-738.
5. Avila-Martin G., Galan-Arriero I., Gomez-Soriano J., Taylor J. Treatment of rat spinal cord injury with the neurotrophic factor albumin-oleic acid: translational application for paralysis, spasticity and pain. PLoS One 2011, 6:e26107.
6. Becker L., Mito T., Takashima S., Onodera K. Growth and development of the brain in Down syndrome. Prog. Clin. Biol. Res. 1991, 373:133-152.
7. Cardenas A.M., Rodriguez M.P., Cortes M.P., Alvarez R.M., Wei W., Rapoport S.I., Shimahara T., Caviedes R., Caviedes P. Calcium signals in cell lines derived from the cerebral cortex of normal and trisomy 16 mice. Neuroreport 1999, 10:363-369.
8. Caviedes P., Ault B., Rapoport S.I. The role of altered sodium currents in action potential abnormalities of cultured dorsal root ganglion neurons from trisomy 21 (Down syndrome) human fetuses. Brain Res. 1990, 510:229-236.
9. Caviedes P., Koistinaho J., Ault B., Rapoport S.I. Effects of nerve growth factor on electrical membrane properties of cultured dorsal root ganglia neurons from normal and trisomy 21 human fetuses. Brain Res. 1991, 556:285-291.
10. Chen Y., Dyakin V.V., Branch C.A., Ardekani B., Yang D., Guilfoyle D.N., Peterson J., Peterhoff C., Ginsberg S.D., Cataldo A.M., Nixon R.A. In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model. Neurobiol. Aging 2009, 30:1453-1465.
11. Cheng A., Haydar T.F., Yarowsky P.J., Krueger B.K. Concurrent generation of subplate and cortical plate neurons in developing trisomy 16 mouse cortex. Dev. Neurosci. 2004, 26:255-265.
12. Clarke C.S., Bannon F.J. Serum albumin in Down syndrome with and without Alzheimer's disease. Ir. J. Med. Sci. 2005, 174:4-8.
13. Corsi P., Coyle J.T. Nerve growth factor corrects developmental impairments of basal forebrain cholinergic neurons in the trisomy 16 mouse. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:1793-1797.
14. Coyle J.T., Oster-Granite M.L., Gearhart J.D. The neurobiologic consequences of Down syndrome. Brain Res. Bull. 1986, 16:773-787.
15. Demeter E., Sarter M. Leveraging the cortical cholinergic system to enhance attention. Neuropharmacology 2013, 64(1):294-304.
16. Dierssen M., de Lagran M.M. DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A): a gene with dosage effect during development and neurogenesis. ScientificWorldJournal 2006, 6:1911-1922.
17. Dowjat W.K., Adayev T., Kuchna I., Nowicki K., Palminiello S., Hwang Y.W., Wegiel J. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci. Lett. 2007, 413:77-81.
18. Elul R., Hanley J., Simmons J.Q. Non-Gaussian behavior of the EEG in Down's syndrome suggests decreased neuronal connections. Acta Neurol. Scand. 1975, 51:21-28.
19. Fiedler J.L., Epstein C.J., Rapoport S.I., Caviedes R., Caviedes P. Regional alteration of cholinergic function in central neurons of trisomy 16 mouse fetuses, an animal model of human trisomy 21 (Down syndrome). Brain Res. 1994, 658:27-32.
20. Granda B., Tabernero A., Tello V., Medina J.M. Oleic acid induces GAP-43 expression through a protein kinase C-mediated mechanism that is independent of NGF but synergistic with NT-3 and NT-4/5. Brain Res. 2003, 988:1-8.
21. Guimera J., Casas C., Estivill X., Pritchard M. Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. Genomics 1999, 57:407-418.
22. Hammerle B., Carnicero A., Elizalde C., Ceron J., Martinez S., Tejedor F.J. Expression patterns and subcellular localization of the Down syndrome candidate protein MNB/DYRK1A suggest a role in late neuronal differentiation. Eur. J. Neurosci. 2003, 17:2277-2286.
23. Hattori H., Kanfer J.N., Massarelli R. Stimulation of phospholipase D activity and indication of acetylcholine synthesis by oleate in rat brain synaptosomal preparations. Neurochem. Res. 1987, 12:687-692.
24. Lejeune J., Gautier M., Turpin R. Study of somatic chromosomes from 9 mongoloid children. C. R. Hebd. Seances Acad. Sci. 1959, 248:1721-1722.
25. Machova E., Malkova B., Lisa V., Novakova J., Dolezal V. The increase of choline acetyltransferase activity by docosahexaenoic acid in NG108-15 cells grown in serum-free medium is independent of its effect on cell growth. Neurochem. Res. 2006, 31:1239-1246.
26. Martin V., Fabelo N., Santpere G., Puig B., Marin R., Ferrer I., Diaz M. Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J. Alzheimers Dis. 2010, 19:489-502.
27. Massarelli R., Ferret B., Sorrentino G., Hattori H., Kanfer J.N. Choline acetyltransferase-like activity bound to neuronal plasma membranes. Neurochem. Res. 1988, 13:1193-1198.
28. Mollgard K., Dziegielewska K.M., Saunders N.R., Zakut H., Soreq H. Synthesis and localization of plasma proteins in the developing human brain. Integrity of the fetal blood-brain barrier to endogenous proteins of hepatic origin. Dev. Biol. 1988, 128:207-221.
29. Polo-Hernandez E., De Castro F., Garcia-Garcia A.G., Tabernero A., Medina J.M. Oleic acid synthesized in the periventricular zone promotes axonogenesis in the striatum during brain development. J. Neurochem. 2010, 114:1756-1766.
30. Rachidi M., Lopes C. Molecular and cellular mechanisms elucidating neurocognitive basis of functional impairments associated with intellectual disability in Down syndrome. Am. J. Intellect. Dev. Disabil. 2010, 115:83-112.
31. Rodriguez-Rodriguez R.A., Tabernero A., Velasco A., Lavado E.M., Medina J.M. The neurotrophic effect of oleic acid includes dendritic differentiation and the expression of the neuronal basic helix-loop-helix transcription factor NeuroD2. J. Neurochem. 2004, 88:1041-1051.
32. Rueda N., Florez J., Martinez-Cue C. Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast. 2012, 2012:584071.
33. Saud K., Arriagada C., Cardenas A.M., Shimahara T., Allen D.D., Caviedes R., Caviedes P. Neuronal dysfunction in Down syndrome: contribution of neuronal models in cell culture. J. Physiol. Paris 2006, 99:201-210.
34. Shah S.N. Fatty acid composition of lipids of human brain myelin and synaptosomes: changes in phenylketonuria and Down's syndrome. Int. J. Biochem. 1979, 10:477-482.
35. Tabernero A., Bolanos J.P., Medina J.M. Lipogenesis from lactate in rat neurons and astrocytes in primary culture. Biochem. J. 1993, 294(Pt 3):635-638.
36. Tabernero A., Lavado E.M., Granda B., Velasco A., Medina J.M. Neuronal differentiation is triggered by oleic acid synthesized and released by astrocytes. J. Neurochem. 2001, 79:606-616.
37. Tabernero A., Velasco A., Granda B., Lavado E.M., Medina J.M. Transcytosis of albumin in astrocytes activates the sterol regulatory element-binding protein-1, which promotes the synthesis of the neurotrophic factor oleic acid. J. Biol. Chem. 2002, 277:4240-4246.
38. Tejedor F., Zhu X.R., Kaltenbach E., Ackermann A., Baumann A., Canal I., Heisenberg M., Fischbach K.F., Pongs O. minibrain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron 1995, 14:287-301.
39. Velasco A., Tabernero A., Medina J.M. Role of oleic acid as a neurotrophic factor is supported in vivo by the expression of GAP-43 subsequent to the activation of SREBP-1 and the up-regulation of stearoyl-CoA desaturase during postnatal development of the brain. Brain Res. 2003, 977:103-111.
40. Yates C.M., Simpson J., Gordon A., Maloney A.F., Allison Y., Ritchie I.M., Urquhart A. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res. 1983, 280:119-126.